Jazz Pharmaceuticals’ (JAZZ) Overweight Rating Reiterated at Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report released on Thursday morning,Benzinga reports. Piper Sandler currently has a $163.00 price target on the specialty pharmaceutical company’s stock, down from their prior price target of $166.00.

Several other analysts have also recently weighed in on the company. TD Cowen dropped their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Robert W. Baird boosted their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, November 7th. JPMorgan Chase & Co. lifted their price target on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Three investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $175.33.

Jazz Pharmaceuticals Stock Up 1.3 %

JAZZ opened at $126.67 on Thursday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock’s fifty day simple moving average is $113.65 and its 200 day simple moving average is $110.73. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $134.17. The stock has a market cap of $7.66 billion, a PE ratio of 17.84, a price-to-earnings-growth ratio of 1.05 and a beta of 0.57.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the transaction, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. The trade was a 0.23 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The trade was a 8.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,110 shares of company stock valued at $720,160 over the last 90 days. 4.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Versant Capital Management Inc raised its stake in Jazz Pharmaceuticals by 13,450.0% during the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at about $29,000. EverSource Wealth Advisors LLC lifted its stake in shares of Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 97 shares during the period. GAMMA Investing LLC boosted its position in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares in the last quarter. Finally, Gladius Capital Management LP acquired a new stake in Jazz Pharmaceuticals during the second quarter worth approximately $33,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.